Clevidipine: An ultra short-acting calcium channel antagonist for acute hypertension

Annals of Pharmacotherapy

Volumn 43, Issue 7-8, 2009, Pages 1258-1265

  Kenyon, Kenneth W ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Calcium channel blocker; Clevidipine; Dihydropyridine; Hypertension; Hypertensive crisis

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLEVIDIPINE; GLYCERYL TRINITRATE; NICARDIPINE; NITROPRUSSIDE SODIUM; PLACEBO;

ACUTE KIDNEY FAILURE; ATELECTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDEMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION RATE; INSOMNIA; INTENSIVE CARE; KIDNEY FAILURE; LIVER FAILURE; NAUSEA; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REFLEX TACHYCARDIA; REVIEW; STROKE; TACHYCARDIA; THORAX PAIN; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; PYRIDINES;

EID: 67651089859     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L610     Document Type: Review

References (33)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69-171.
2. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States, 1999-2000: a rising tide. Hypertension 2004;44:398-404.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223 (Pubitemid 40138015)
4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
5. Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs 2008;68:283-297 (Pubitemid 351225810)
6. Marik PE, Varon J. Hypertensive crisis: challenges and management. Chest 2007;131:1949-1962
7. Cheung AT. Exploring and optimum intra/postoperative management strategy for acute hypertension in the cardiac surgery patient. J Card Surg 2006;21:S8-14.
8. Estafanous FG, Tarazi RC. Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol 1980;46:685-694 (Pubitemid 10009825)
9. Noviawaty I, Uzun G, Qureshi AI. Drug evaluation of clevidipine for acute hypertension. Expert Opin Pharmacother 2008;9:2519-2529
10. Reich DL, Bennett-Guerrero E, Bodian CA, Hossain S, Winfree W, Krol M. Intraoperative tachycardia and hypertension are independently associated with adverse outcome in noncardiac surgery of long duration. Anesth Analg 2002;95:273-277 (Pubitemid 34793082)
11. Fontes ML, Aronson S, Mathew JP, et al. Pulse pressure and risk of adverse outcome in coronary bypass surgery. Anesth Analg 2008;107: 1122-1129
12. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med 1996;335:1857-1863 (Pubitemid 26419192)
13. Mangano DT. Cardiovascular morbidity and CABG surgery - a perspective: epidemiology, costs, and potential therapeutic solutions. J Card Surg 1995;10:366-368
14. Briesblatt WM, Stein KL, Wolfe CJ, et al. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol 1990;15:1261-1269 (Pubitemid 20141101)
15. Wolfsthal SD. Is blood pressure control necessary before surgery? Med Clin North Am 1993;77:349-363
16. Aronson S, Boisvert D, Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg 2002;95:1079-1084 (Pubitemid 34441812)
17. Schwieler JH, Ericsson H, Löfdahl P, Thulin T, Kahan T. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol 1999;34:268-274 (Pubitemid 29350509)
18. Product information. Cleviprex (clevidipine butyrate). Parsippany, NJ: The Medicines Company, August 2008.
19. The Medicines Company. The Medicines Company's Cleviprex receives FDA approval [press release]. August 4, 2008. http://themedicinescompany. com (accessed 2008 Sept 9).
20. Nodlander M, Sjöquist PO, Ericsson H, Rydén L. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovas Drug Rev 2004;22:227-250 (Pubitemid 39391191)
21. Ericsson H, Bredberg U, Eriksson U, Jolin-Mellgård Å, Nordlander M, Regårdh CG. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and long-term intravenous infusion in healthy volunteers. Anesthesiology 2000;92:993-1001. (Pubitemid 30180975)
22. Ericsson H, Fakt C, Jolin-Mellgård Å, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol 1999;47:531-538 (Pubitemid 29199725)
23. Ericsson H, Fakt C, Höglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Pharmacol 1999;1:61-67 (Pubitemid 29144102)
24. Zhang JG, Dehal SS, Ho T, et al. Human cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite H152/81. Drug Metab Dispos 2006;34:734-737
25. Kieler-Jensen N, Jolin-Mellgård Å, Nodlander M, Ricksten SE. Coronary and systemic hemodynamic effects of clevidipine, an ultra-shortacting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand 2000;44:186-193 (Pubitemid 30090268)
26. Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients. A dose-finding study. Anesthesiology 2002; 96:1086-1094
27. Powroznyk AVV, Vuylsteke A, Naughton C, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 2003;20:697-703. (Pubitemid 37047744)
28. Smith WB, Marbury TC, Komjathy SF, Sumeray M. The pharmacokinetic and pharmacodynamics of clevidipine after prolonged infusion in patients with essential hypertension (abstract 221). Pharmacotherapy 2007;27:280-281
29. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1 (ESCAPE-1). Anesth Analg 2007;105:918-925 (Pubitemid 47479301)
30. Singla N, Warltier DC, Gandhi SD, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg 2008;107:59-67.
31. Pollack CV, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Peacock WF. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med 2009;53:329-338 DOI 10.1016/j.annemergmed.2008.04.025
32. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008;107:1110-1121
33. The Medicines Company. The Medicines Company resumes clevidipine phase III program; phase III interim data review affirms safety profile [press release]. October 19, 2005. http://themedicinescompany.com (accessed 2008 Sept 21).